[Retracted] Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World
Table 3
Correlation between tumor sampling characteristics of patients and PD-L1 expression.
ALL
value
()
()
()
Sampling method
0.485
Ultrasound puncture
1 (1.27%)
11 (7.48%)
5 (7.14%)
17 (5.74%).
CT puncture
34 (43.0%)
45 (30.6%)
25 (35.7%)
104 (35.1%)
Ultrasonic tracheoscope
8 (10.1%)
12 (8.16%)
3 (4.29%)
23 (7.77%)
Bronchoscope
29 (36.7%)
69 (46.9%)
29 (41.4%)
127 (42.9%)
Operation
3 (3.80%)
4 (2.72%)
3 (4.29%)
10 (3.38%)
Chest puncture
3 (3.80%)
5 (3.40%)
5 (7.14%)
13 (4.39%)
Thoracoscope
1 (1.27%)
1 (0.68%)
0 (0.00%)
2 (0.68%)
Specimen type
0.676
Organization
73 (92.4%)
138 (93.9%)
62 (88.6%)
273 (92.2%)
Cells
3 (3.80%)
5 (3.40%)
5 (7.14%)
13 (4.39%).
Surgical specimens
3 (3.80%)
4 (2.72%)
3 (4.29%)
10 (3.38%)
Sampling position
0.923
Primary tumor
66 (83.5%)
121 (82.3%)
57 (81.4%)
244 (82.4%)
Lymph node
8 (10.1%)
17 (11.6%)
7 (10.0%)
32 (10.8%)
Pleural effusion
3 (3.80%)
5 (3.40%)
5 (7.14%)
13 (4.39%)
Other metastases1
2 (2.53%)
4 (2.72%)
1 (1.43%)
7 (2.36%)
Treatment or not2
0.986
Treatment-naive3
69 (87.3%)
126 (85.7%)
61 (87.1%)
256 (86.5%)
Retreatment4
9 (11.4%)
20 (13.6%)
9 (12.9%)
38 (12.8%)
Unknown5
1 (1.27%)
1 (0.68%)
0 (0.00%)
2 (0.68%)
TNM
0.486
I
4 (5.06%)
4 (2.72%)
1 (1.43%)
9 (3.04%)
II
2 (2.53%)
4 (2.72%)
1 (1.43%)
7 (2.36%)
III
21 (26.6%)
56 (38.1%)
21 (30.0%)
98 (33.1%)
IV
52 (65.8%)
83 (56.5%)
47 (67.1%)
182 (61.5%)
Specimen storage time6
51.0 (133)
67.6 (187)
45.1 (113)
44.5 (93.4)
0.43
TNM: stage of lung cancer, International Association for the Study of Lung Cancer 8th edition. 1Other metastases: except lymph nodes, pleural effusion, and other metastases, such as bone. 2Whether the patient received antitumor therapy at the time of PD-L1 test. 3The patient never received antitumor therapy at the time of PD-L1 test. 4Retreatment: the relevant antitumor therapy for lung cancer, including chemotherapy, targeted therapy, immunotherapy, radiotherapy, and antitumor Chinese medicine therapy. 5Unknown: specific treatment options are not available to patients. 6Specimen storage duration: the duration from tissue sampling to the detection of PD-L1.
